The treatment of nonmetastatic high grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer treatment and research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-1-4419-0284-9_14PMID 20213396
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma

  2007cited by this paper
• Local recurrence and local control of non‐metastatic osteosarcoma of the extremities: A 27‐year experience in a single institution

  2007cited by this paper
• Prognostic value of P-glycoprotein in high-grade osteosarcoma.

  2007cited by this paper
• Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.

  2007cited by this paper
• Follow-up study of long-term survivors of osteosarcoma in the prechemotherapy era.

  2006cited by this paper
• Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy

  2006cited by this paper
• Late Relapse in Osteosarcoma

  2006cited by this paper
• May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.

  2006cited by this paper
• Second Malignant Neoplasm in Patients With Osteosarcoma of the Extremities Treated With Adjuvant and Neoadjuvant Chemotherapy

  2006cited by this paper
• Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate

  2005cited by this paper
• Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

  2005cited by this paper
• THE CLASSIC: Recent Advances in Chemotherapy of Metastatic Osteogenic Sarcoma

  2005cited by this paper
• Evaluation of P‐glycoprotein, HER‐2/ErbB‐2, p53, and Bcl‐2 in primary tumor and metachronous lung metastases in patients with high‐grade osteosarcoma

  2004cited by this paper
• Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.

  2004cited by this paper
• Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival.

  2003cited by this paper
• Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.

  2003cited by this paper
• Fertility in Male Patients Treated With Neoadjuvant Chemotherapy for Osteosarcoma

  2003cited by this paper
• High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study.

  2002cited by this paper
• High Dose Ifosfamide in Combination with High Dose Methotrexate, Adriamycin and Cisplatin in the Neoadjuvant Treatment of Extremity Osteosarcoma: Preliminary Results of an Italian Sarcoma Group/Scandinavian Sarcoma Group Pilot Study

  2002cited by this paper
• Neoadjuvant Chemotherapy for High Grade Osteosarcoma of the Extremities: Long-Term Results for Patients Treated According to the Rizzoli IOR/OS-3b Protocol

  2001cited by this paper
• Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol.

  2001cited by this paper
• Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute.

  2001cited by this paper
• Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report.

  2000cited by this paper
• Reproductive functions in female patients treated with adjuvant and neoadjuvant chemotherapy for localized osteosarcoma of the extremity

  2000cited by this paper
• Nonmetastatic Osteosarcoma of the Extremity: Results of a Neoadjuvant Chemotherapy Protocol (IOR/OS-3) with High-dose Methotrexate, Intraarterial or Intravenous Cisplatin, Doxorubicin, and Salvage Chemotherapy Based on Histologic Tumor Response

  1999cited by this paper
• Expression of HER2/erbB-2 correlates with survival in osteosarcoma.

  1999cited by this paper
• P‐glycoprotein expression in osteosarcoma: A basis for risk‐adapted adjuvant chemotherapy

  1999cited by this paper
• Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy.

  1997cited by this paper
• Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome.

  1995cited by this paper
• THE CLASSIC: Osteogenic Sarcoma: A Study Based on 133 Patients

  1991cited by this paper
• Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high‐dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS‐86)

  1990cited by this paper
• Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities the istituto rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin

  1990cited by this paper
• Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study.

  1986cited by this paper
• Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy

  1982cited by this paper
• The treatment of osteosarcoma of the extremities: Twenty year's experience at the istituto ortopedico rizzoli

  1981cited by this paper
• Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery

  1979cited by this paper
• Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54.

  1977cited by this paper
• Vaccine trials for osteogenic sarcoma: A Preliminary Report

  1973cited by this paper
• Doxorubicin in disseminated osteosarcoma.

  1972cited by this paper
• Osteosarcoma.An assessment of management with particular reference to primary irradiation and selective delayed amputation

  1972cited by this paper
• Doxorubicin in Disseminated

  1972cited by this paper
• Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases.

  1970cited by this paper
• Osteogenic sarcoma; a study based on 133 patients.

  1955cited by this paper

• Advances in Surgical Management of Malignant Tumors of the Distal Tibia

  2025cites this paper
• Iron oxide nanoparticles coated with bioactive materials: a viable theragnostic strategy to improve osteosarcoma treatment

  2025cites this paper
• Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model

  2024cites this paper
• Impact of delay of local control in nonmetastatic extremity primary osteosarcoma

  2023cites this paper
• Reconstruction with a double-constrained implant design after complex shoulder extra-articular resection

  2023cites this paper
• Cancer-Specific Survival after Limb Salvage versus Amputation in Children and Adolescents with Osteosarcoma: A Population-Based Analysis with Propensity Score Matching

  2023cites this paper
• Three-Dimensional CT and 3D MRI of Hip- Important Aids to Hip Preservation Surgery.

  2023cites this paper
• Nickel-titanium shape memory alloy embracing fixator benefits the determination of the implantation angle of prosthesis stem in tumor-type artificial joint replacement.

  2022cites this paper
• Tetraspanin 7 promotes osteosarcoma cell invasion and metastasis by inducing EMT and activating the FAK-Src-Ras-ERK1/2 signaling pathway

  2022cites this paper
• Late effects of osteosarcoma and its treatment in pediatric patients: A single-center experience.

  2021cites this paper
• Chemotherapy for osteosarcoma: Literature review and experience of Taipei veterans general hospital

  2021cites this paper
• Combination Therapy of Cisplatin and other Agents for Osteosarcoma: A Review

  2021cites this paper
• The Role of Nickel-titanium Shape Memory Alloy Embracing Fixator in Determination of the Implantation Angle of Hip Tumor Prosthesis Stem Following Tumor Resection and the Analysis of Its Efficacy: a Retrospective Study

  2020cites this paper
• Evaluation of factors affecting survival rate in primary bone sarcomas with extremity and pelvis involvement.

  2020cites this paper
• MicroRNA‑652 promotes cell proliferation and osteosarcoma invasion by directly targeting KLF9

  2020cites this paper
• MicroRNA-652 promotes cell proliferation and osteosarcoma invasion by directly targeting KLF9.

  2020cites this paper
• Osteosarcoma: a comprehensive review

  2018cites this paper
• MicroRNA-432 is downregulated in osteosarcoma and inhibits cell proliferation and invasion by directly targeting metastasis-associated in colon cancer-1.

  2018cites this paper
• Outcomes and Prognostic Factors for Non-metastatic Osteosarcoma of the Extremity

  2018cites this paper
• Therapeutic effect of neoadjuvant chemotherapy combined with curettage to treat distal femoral osteosarcoma

  2017cites this paper
• Cancer stem cells of sarcoma

  2016cites this paper
• Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma: A Single-institution Experience

  2016influential citation
• Sulforaphane enhances cisplatin sensitivity in human osteosarcoma cells through upregulation of p 53-p 21 pathway by enhancing G 1 arrest

  2016cites this paper
• The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.

  2016cites this paper
• Delay in Diagnosis and Its Effect on Clinical Outcome in High‐grade Sarcoma of Bone: A Referral Oncological Centre Study

  2016cites this paper
• Amputation Versus Limb-Salvage Surgery in Patients with Osteosarcoma: A Meta-analysis

  2016cites this paper
• Are Complications Associated With the Repiphysis® Expandable Distal Femoral Prosthesis Acceptable for Its Continued Use?

  2015cites this paper
• Presentation and Long-term Outcome of High-grade Osteosarcoma: A Single-institution Experience

  2015cites this paper
• Prognostic Factors and Treatment Results of High-Grade Osteosarcoma in Norway: A Scope Beyond the “Classical” Patient

  2015cites this paper
• Osteosarcoma treatment - where do we stand? A state of the art review.

  2014cites this paper
• Anti-Tumour Treatment Osteosarcoma treatment – Where do we stand ? A state of the art review

  2014cites this paper
• Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma

  2014influential citation
• MicroRNA-199a-3p and microRNA-34a regulate apoptosis in human osteosarcoma cells

  2014cites this paper
• Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma.

  2014cites this paper
• Alkaline phosphatase level change in patients with osteosarcoma: its role as a predictive factor of tumor necrosis and clinical outcome.

  2014cites this paper
• New Medical/Biologic Paradigms in the Treatment of Bone Tumors

  2014cites this paper
• Osteosarcoma of the mobile spine.

  2013cites this paper
• The Current and Future Therapies for Human Osteosarcoma.

  2013cites this paper
• Effectiveness of sulforaphane as a radiosensitizer for murine osteosarcoma cells.

  2013cites this paper
• Osteosarcoma: Differential Diagnostic Considerations.

  2012cites this paper
• Sensitization of human osteosarcoma cells to Vγ9Vδ2 T‐cell‐mediated cytotoxicity by zoledronate

  2012cites this paper
• Columbamine suppresses the proliferation and neovascularization of metastatic osteosarcoma U2OS cells with low cytotoxicity.

  2012cites this paper
• Role of Neo-Adjuvant Chemotherapy in the Treatment of Osteosarcoma

  2012cites this paper
• Analysis of the efficacy and prognosis of limb-salvage surgery for osteosarcoma around the knee.

  2012cites this paper
• Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide

  2011cites this paper
• Imaging of soft tissue and osseous sarcomas of the extremities.

  2011cites this paper
• Malignant Tumors of Bone

  2008cites this paper